QuidelOrtho’s New Certified Analyzer Program Expands Access to Diagnostic Testing

QuidelOrtho Launches Certified Analyzer Program

QuidelOrtho Corporation has recently introduced an innovative initiative aimed at improving access to high-quality diagnostic testing across rural and community hospitals in the United States. The Certified Analyzer Program is specifically designed for smaller medical facilities, such as clinics and physician office labs with fewer than 100 beds. By utilizing certified VITROS™ analyzers, the program promises to deliver reliable results and excellent service at a significantly reduced cost.

Enhancing Healthcare Accessibility

Audra Jones, the Senior Vice President for North America at QuidelOrtho, emphasized that their primary mission is to support healthcare providers in delivering excellent diagnostic services to patients. She stated, "By repurposing and rigorously certifying high-performing analyzers, we aim to expand access to reliable diagnostic technology for healthcare facilities that play a critical role in their communities."

To ensure the quality of the analyzers, each unit undergoes a stringent certification process at QuidelOrtho’s Rochester facility. This process includes more than 140 system checks, adjustments to functionality, as well as hardware cleaning and replacement. This comprehensive testing guarantees adherence to QuidelOrtho’s high standards while providing a 12-month warranty on service and support.

Advanced Technology at a Fraction of the Cost

The program features certified units from the VITROS XT 7600 and 5600 Integrated Systems and the VITROS 3600 Immunodiagnostic System. These platforms are specifically engineered to assist community laboratories with a variety of tests, ranging from general chemical analyses to immunoassays and drug screening. This feature enhances the capabilities of small health facilities, ensuring they can meet the diverse needs of their patient populations effectively.

Jones added, "We are proud to support healthcare providers who are the backbone of their communities, backed by our award-winning service and top-ranked customer satisfaction. This program isn't just about cost-effectiveness; it aims to improve accessibility to diagnostic solutions for healthcare providers in underserved regions."

Commitment to the Future of Diagnostics

With this launch, QuidelOrtho continues its dedication to advancing diagnostic solutions to pave the way for a healthier future. The Certified Analyzer Program not only focuses on providing affordable tools but also aims to empower healthcare providers. This initiative will ensure that even the most underserved communities will have access to reliable medical technologies.

For further details on this initiative and other advancements in their diagnostic offerings, QuidelOrtho encourages interested parties to visit their website at quidelortho.com and follow them on social media platforms such as LinkedIn, Facebook, and X.

About QuidelOrtho Corporation

QuidelOrtho Corporation (Nasdaq: QDEL) is recognized as a global leader in the field of in vitro diagnostics. The company specializes in developing and manufacturing innovative solutions that transform data into actionable understanding for people worldwide. With a history steeped in innovation, QuidelOrtho collaborates with healthcare customers globally to enhance diagnostic services, ensuring that insights and solutions are readily available when needed, from clinical settings to the patient's home.

For media inquiries or more information about the Certified Analyzer Program, please reach out to their media contact, D. Nikki Wheeler, Senior Director of Corporate Communications, or to Juliet Cunningham, Vice President of Investor Relations for investor-related queries.